Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine and Vorinostat with FLAG in Relapsed/Refractory AML
NCT03263936Phase 1Completed
- Sponsor
- Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium
- Start
- Jul 2017
- Primary completion
- Jul 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of decitabine and vorinostat in acute myeloid leukemia (AML), sponsored by Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium. Primary endpoint: The Dose of Decitabine That Can be Safely Given With Vorinostat, Fludarabine, High Dose Cytarabine and G-CSF (FLAG) at 9 weeks. Started Jul 2017; status: completed.
02
Drugs
decitabinevorinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03263936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03263936.